ClinicalTrials.gg
Not yet recruitingNCT07946068Updated Nov 18, 2026

Aleniglipron Renal Impairment Study

A Phase 1 interventional study of Aleniglipron in Renal Impairment and Severe Renal Impairment, sponsored by Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics. Not yet recruiting at 1 site in United States. Open to participants aged 18 Years to 85 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-18.

Sponsored by Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics (part of Structure Therapeutics) · Phase 1, Interventional, and Treatment

Updated Nov 18, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
16
Allocation
Non-randomized
Ages
18 Years to 85 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 554 studies in Renal Insufficiency with a site in United States — 41 open to participants now, 57 under way, 3 of them phase 3. Renal Insufficiency · United States.

Planned enrollment
358th of 469
16 · median 32
Started
2026
with 15 others
Phase 1
233 of 554
15 open now
Primary completion
2027-03
later than 23 of 56 live
Registered
554th of 554
by date

Among the 554 studies in Renal Insufficiency with a site in United States, this one is the 358th largest by planned enrollment of the 469 interventional ones that give a count, is one of 16 that started in 2026, is one of 233 in phase 1, reaches primary completion later than 23 of the 56 other live ones, and was the 554th registered.

Renal Insufficiency

1,414 studies on the registry are indexed under Renal Insufficiency; 147 are open to participants now.

Browse Renal Insufficiency studies →

Open to participants now

41 of the 554 studies in Renal Insufficiency with a site in United States are open now. Recruiting first, the newest first:

36 more — sign in →

All 41 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 93 Renal Insufficiency studies recruiting now, 49 (53%) set no upper age limit and 19 (20%) stop at 75 or younger; 8 take children under 18; 15 take healthy volunteers.

This study: 18 Years to 85 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 554 studies in Renal Insufficiency with a site in United States, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the effect of severe RI on IHD on the PK of aleniglipron to establish scientifically guided dosing recommendations in these special patient populations.

03

Conditions studied

  • Renal Impairment
  • Severe Renal Impairment

Browse trials for

Keywords

  • Renal Impairment
  • Renal
04

Who can participate

Ages eligible
18 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Is an adult, male or female, ≥ 18 to 85 years of age (inclusive), at screening.
  2. ≥ 17.0 and ≤ 40.0 kg/m2 and weight of at least 40.0 kg
  3. Understands the study procedures in the ICF and is willing and able to comply with the protocol and communicate effectively with study personnel.
  4. Group 1 only: Participant has severe RI maintained on stable regimen of high-flux HD at least 3 times per week for at least 3 months
  5. Group 2 only: Has normal renal function with ≥ 90 mL/min

Exclusion criteria

Exclusion Criteria:

  1. History or presence of alcohol or drug abuse within the past 6 months prior to the dosing.
  2. History or presence of or idiosyncratic reaction to the study drug or related compounds.
  3. Female participant with a positive pregnancy test at screening or at first check-in or who is lactating or breastfeeding
  4. Has taken medications intended to promote weight loss within 3 months or 5 half-lives, whichever is longer, prior to screening, including, but not limited to GLP-1 RAs.
  5. Received an product in another clinical study within 30 days or 5 half-lives (if known) prior to first dosing, whichever is longer.
  6. Has a history or presence of medical or psychiatric condition or disease, any illness that, in the opinion of the PI or designee, might confound the results of the study or poses an additional risk to the participant by their participation in the study
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
16 participants (estimated)

Study arms

  • Experimental
    Group 1: Participants with severe renal impairment on intermittent hemodialysis

    Aleniglipron administered orally

    Drug: Aleniglipron

  • Experimental
    Group 2: Participants with normal renal function

    Aleniglipron administered orally

    Drug: Aleniglipron

Interventions

06

What researchers measure

Primary outcomes

  1. Plasma PK parameters for aleniglipron including, but not limited to AUC0-t

    Time frame: Baseline to Day 3

  2. Plasma PK parameters for aleniglipron including, but not limited to AUC0-inf

    Time frame: Baseline to Day 3

  3. Plasma PK parameters for aleniglipron including, but not limited to Cmax

    Time frame: Baseline to Day 3

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Dec 2026; primary completion for Mar 2027, 3 months later.

Of 213 industry-sponsored phase 1 interventional studies under Renal Insufficiency, half reached primary completion within 8 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 15. This study's planned 3 months is below that.

Counting every sponsor, half of 231 studies reached it within 8 months; a quarter within 5 and three quarters within 16.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 13, 2026
First posted
Nov 18, 2026
StartEst.
Dec 2026
Primary completionEst.
Mar 2027
CompletionEst.
Mar 2027
Last update
Nov 18, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 18, 2026
Show all 1 update
  1. Nov 18, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07946068
Responsible party
Sponsor
First posted
Nov 18, 2026
Start date
Dec 2026 (estimated)
Primary completion
Mar 2027 (estimated)
Completion
Mar 2027 (estimated)
Last update
Nov 18, 2026

Study contacts

Medical Director
Contact
GSBRClinicalTrials@Structuretx.com
650-457-1959

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Aleniglipron

Start the discussion